The development of new pharmaceuticals with high quality and safety requires medical discoveries and technical innovation as well as long-term continuous effort. We began our research into recombinant human serum albumin in the early 1980s, when the world launched an effort to develop pharmaceuticals with biotechnologies. Although blood products including albumin were highly demanded, most of them were dependent on foreign imports because of the limited availability of their raw materials in Japan. To change this situation for the better and improve its safety had been great tasks. While many biobusinesses engaged in fierce competition, we had overcome the diverse problems associated with purity and productivity, and finally succeeded in establishing methods of mass production of high-quality recombinant human serum albumin.

Following this success, in 1996, we established BIPHA CORPORATION in Chitose City of Hokkaido Prefecture for its commercial production. Our product was approved in October, 2007, and it is the world’s first approved recombinant human serum albumin. At present, our products are released to medical institutions all over Japan through its marketing license holder, Mitsubishi Tanabe Pharma Corporation with brand names of ‘Medway Injection 25%’. We place our dreams in the future of biotechnology, and we continue our challenges and efforts to fulfill our mission of contributing to healthier lives of people through our pharmaceuticals.

**Major Product Lines** (excluding medical use):
- rHSA 50mL w/o stabilizer
- rHSA 500mL w/o stabilizer
- rHSA 25% 50mL w/ stabilizer

---

**Corporate Overview**

Address: 1007-124, Izumisawa, Chitose, Hokkaido 0660051 Japan
Company Representative: Takehiko Fujii, president
Phone: +81-123-28-8180  FAX: +81-123-28-8150
URL: http://www.bipha.co.jp/
Foundation: November, 1996
Capital: 7,500,000,000 Yen
Employees: 79
Category of Business: Manufacture of medicinal chemicals
Business Overview: Manufacturing genetically modified human serum albumin product
Contact: Hiroshi Okada, manager, General Planning Group
E-mail: okada.hiroshi@mf.mt-pharma.co.jp